Myelofibrosis
Conditions
Brief summary
This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.
Interventions
DRUGTQ05105 tablets
TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
Rifampicin is a strong inducer of CYP3A.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* At the time of signing the informed consent, males or females between 18 and 45 years of age; * Female weight ≥ 45 kg, male weight ≥ 50 kg, with a body mass index (BMI) between 19 and 26 kg/m2. * Subjects in good health, as determined by a medical history, vital signs, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations; * Subjects can comply with the study procedures, voluntarily participate in the study, and sign the informed consent in person.
Exclusion criteria
* Subjects: preexisting or existing circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic disorders or abnormalities, or related chronic or acute diseases, the investigator assesses that it is not appropriate to participate in the trial； * Subjects with Systemic/local acute infection before taking the study drug; * Subjects who have a history of specific allergies, or allergic conditions (such as allergies to two or more drugs, environments, or foods), or are known to be allergic to components or analogs of the study drug; * Subjects who have difficulty in swallowing or have any gastrointestinal disorder that affects drug absorption at the time of screening； * Subjects who cannot receive venous indwelling needle for blood sample collection； * Subjects who drank regularly in the 6 months prior to first dosing, such as those who drank more than 14 units of alcohol per week or who had a positive alcohol breath test at the time of screening； * Subjects who had a history of major surgery, or had taken the study drug, or had participated in other drug clinical trials within 3 months prior to initial dosing； * Subjects who donated blood or lost significant amounts of blood within 3 months prior to initial dosing； * Subjects who had used drugs within 3 months prior to first dosing, or tested positive for drugs, or had a history of drug abuse within 5 years prior to screening； * Subjects who smoked more than 5 cigarettes per day in the 3 months prior to initial dosing or who could not stop using any tobacco products during the trial； * Subjects who consumed excessive amounts of tea, coffee, and/or caffeinated beverages daily in the 30 days prior to initial dosing； * Subjects who have used any drug that inhibits or induces liver metabolism of the drug in the 30 days prior to initial dosing； * Subjects who have taken any prescription, over-the-counter, herbal, or health product in the 14 days prior to initial dosing； * Subjects who have taken a special diet or other factors affecting drug absorption, distribution, metabolism, or excretion within 7 days prior to initial dosing； * Subjects who ingested chocolate, any caffeinated, or xanthine-rich food or drink 48 hours before first dosing； * Subjects who have special dietary requirements and cannot follow a uniform diet； * Female subjects of child-bearing potential； * Subjects judged by the investigator to be unsuitable to participate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) | Up to 10 days. | Maximum plasma drug concentration after administration. |
| Time to reach Cmax (Tmax) | Up to 10 days. | Time to reach the maximum plasma concentration after administration. |
| Elimination half-life (t1/2) | Up to 6 days. | The elimination half-life (t1/2) after oral dose of TQ05105 tablets and Itraconazole capsule. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of adverse events (AE) | Up to 30 days. | Including all adverse events (AE) and serious adverse events (SAE). |
Countries
China
Outcome results
None listed